SXI Is a Great Business at a 32x Earnings Price Tag

Standex's issue is price, not business quality

This is not a broken story. It is a valuation problem. Standex has already done what quality industrial investors want: the stock is up 230.5% over the past five years and 78.7% over the last year. That changes the setup. The business still looks solid, but the entry price leaves less room for error. You are no longer buying a bargain-bin opportunity; you are paying up for durability.

What the market is pricing in

Standex is trading near $322.50, above the average 12-month analyst target of $298.67. With a 32.32 P/E as of May 1, 2026, investors are still paying a premium multiple for what looks like a well-run franchise. That implies expectations for steady growth and margin resilience, not just one strong quarter.

The operating case still matters. Demand has stayed reasonably firm, newer products remain relevant, and management has held onto margin discipline. But that is precisely why price matters now. Bulls can argue a durable compounder deserves a richer multiple if it keeps earning it. Bears can argue the stock is already priced ahead of the Street's own target range, so even a small stumble could pressure the valuation.

Why investors were willing to pay up

That premium did not come from nowhere. It reflects a pattern that held for at least three straight quarters.

Demand held up across the quarter stack

In Q2, sales rose 16.6% year over year and 6.4% organically, while order flow improved with record quarterly order intake and book to bill of 1.04. In Q3, sales still increased 8.1% year over year with 6.5% organic growth, and book to bill remained above 1.0 at 1.05. By Q4, organic sales were still up 7.7%, order intake reached about $270 million, and book to bill rose to 1.18.

A book-to-bill ratio above 1.0 means new demand is running ahead of shipments. Over multiple quarters, that gives the business more visibility into future revenue.

New products and fast-growth markets stayed important

The mix also looks healthier than a plain volume recovery. In Q2, new-product sales grew about 13% and fast-growth-market sales accounted for about 28% of total sales. In Q3, new-product sales grew about 40% and fast-growth-market sales were more than 30% of total sales. By Q4, new-product sales grew 43% and fast-growth-market sales were 31% of total sales.

That does not guarantee superior economics, but it does suggest Standex is not relying only on selling more of the same. Newer products and faster-growing end markets can support pricing power and margin resilience.

Margin discipline held, even if the headline margin story needs context

Adjusted operating margin was 19.0% in Q2, up 30 basis points year over year. It improved again to 19.7% in Q3. In Q4, adjusted EPS reached a record $2.45, and Standex finished FY26 with record adjusted gross margin and adjusted operating margin.

That is the core of the quality case: growth was not just showing up in revenue, but also in profitability. The caution, though, is that premium multiples need this discipline to continue. If growth slows or margins slip, the market can reset the price tag quickly.

How to think about SXI from here

Why the bull case still makes sense

A business this steady can still work for investors if it keeps compounding through the multiple. At roughly 32.32 P/E as of May 1, 2026, Standex is being valued like a quality industrial compounder, not a turnaround. Even the Street remains constructive, with a Moderate Buy consensus and targets that extend to $350.00.

Why the premium still matters

The risk is that expectations are already fairly full. If the stock stays near $322.50 while the average 12-month analyst target remains below that level, future returns depend more on continued execution than on multiple expansion. A merely decent quarter could be enough to pressure the multiple, even if the underlying business stays sound.

For current holders, that is a reason to respect the franchise without assuming the market will keep rewarding it automatically. For potential buyers, waiting for better price or clearer confirmation is not the same as missing out. At a 32x earnings price tag, entry choice matters more than usual.